Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C
Article first published online: 8 SEP 2005
Journal of Gastroenterology and Hepatology
Volume 21, Issue 3, pages 575–580, March 2006
How to Cite
KOKOGLU, O. F., UÇMAK, H., HOSOGLU, S., CETINKAYA, A., KANTARCEKEN, B., BUYUKBESE, M. A. and ISIK, I. O. (2006), Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. Journal of Gastroenterology and Hepatology, 21: 575–580. doi: 10.1111/j.1440-1746.2005.04008.x
- Issue published online: 16 MAR 2006
- Article first published online: 8 SEP 2005
- Accepted for publication 7 March 2005.
- chronic hepatitis C;
- chronic renal failure;
- pegylated interferon;
Background and Aim: Hepatitis C virus (HCV) is prevalent in hemodialysis (HD) patients. These patients experience more side-effects with antiviral treatment. The aim of the present study was to evaluate the efficacy and tolerability of pegylated interferon (PEG-IFN) α-2a in chronic hemodialysis patients with chronic hepatitis C.
Methods: Twenty-five patients were included into the study. All of the patients were interferon naive, anti-HCV antibodies positive and polymerase chain reaction HCV-RNA positive. Twelve of the patients received PEG-IFN α-2a at a dose of 135 µg weekly for 48 weeks (Group 1). The remaining 13 patients who received no specific treatment were used as controls (Group 2). The patients were prospectively followed up for a period of 18 months. Biochemical and virological responses were evaluated at the end of the study period (end-of-treatment response) and 6 months after the completion of therapy (sustained response).
Results: Virological end-of-treatment response was observed in 10 patients (83.4%) in Group 1 and one patient (7.7%) in Group 2 (P < 0.001). Sustained virological response was observed in nine patients (75%) in Group 1 and one patient (7.7%) in Group 2 (P < 0.001). Alanine aminotransferase (ALT) levels were initially increased in seven patients in Group 1 and normalized in five of these patients at the end of the treatment and sustained biochemical response was 71.4%. In contrast, ALT levels in Group 2 were initially high in five patients and normalized in two of them (40%) at the end of the 48 weeks. Even if most of the patients experienced several side-effects (anemia 75%, fatigue 58.3%, thrombocytopenia 33.3% and leukopenia 33.3%), they did not impose the discontinuation of the treatment.
Conclusion: The present study showed that PEG-IFN α-2a for 48 weeks is efficacious and well tolerated in hemodialysis patients with HCV.